Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| EGFR-mutated non-small Cell Lung Cancer | IND Approval | China | 17 Aug 2026 | |
| Central Nervous System Diseases | Preclinical | China | 22 Apr 2025 |





